Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 8Leukemia, Myeloid, Chronic-Phase 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Sarcoma 4Melanoma 4Gastrointestinal Stromal Tumors 4Leukemia, Myeloid, Accelerated Phase 3Sarcoma, Synovial 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Glioma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Refractory Desmoplastic Small Round Cell Tumors 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neurofibromatoses 1

Interventions

Temozolomide 23Radiotherapy 15Radiation 7Bevacizumab 6temsirolimus 5Sirolimus 5Radiotherapy, Conformal 5Erlotinib Hydrochloride 5Carmustine 5Carboplatin 5Radiotherapy, Intensity-Modulated 4Everolimus 4Vorinostat 3Irinotecan 3veliparib 2tipifarnib 2plerixafor 2pembrolizumab 2atezolizumab 2Surgical Procedures, Operative 2Sorafenib 2Gefitinib 2Fluorodeoxyglucose F18 2Cilengitide 2Chemotherapy, Adjuvant 2vatalanib 1vandetanib 1terameprocol 1tandutinib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gliosarcoma × Imatinib Mesylate × Clear all
NCT00010049 2018-06-27

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
105 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡